New US$35M partnership to advance blood disorder therapies
2025-05-19
(Press-News.org)
A new frontier into advancing treatments for children and adults with bone marrow failure, leukaemia and other blood disorders will be achieved under a new partnership between Murdoch Children’s Research Institute (MCRI) and US biotechnology company Retro Biosciences.
MCRI, a flagship member of the Melbourne Biomedical Precinct and the Melbourne arm of the international research consortium, the Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW, has today announced a significant research and commercial licensing agreement with Retro Biosciences. The agreement will advance a blood stem cell breakthrough, discovered by MCRI scientists last year, that could pave the way for new therapies for patients around the world.
The partnership, worth over US$35 million, will further develop MCRI’s field-leading research and technology by licensing the blood stem cell discovery IP to Retro Biosciences for the development of new, personalised therapies.
More than 90,000 blood stem cell transplants are performed globally every year to treat blood diseases. Of these, over 36,000 involve transplants from donors to treat leukaemia or bone marrow failure syndromes. But not all patients receive a perfectly matched transplant, which can result in severe illness or death, as mismatched donor cells may attack the patient’s own tissues.
In a world-first discovery in 2024, MCRI researchers created blood stem cells from human cells in the lab. These cells closely resembled those in the human body. The development lays the groundwork for a patient’s own perfectly matched cells to be used in blood stem cell and bone marrow transplants.
MCRI Associate Professor Elizabeth Ng, whose team was behind the research, said; “We have shown that we can take any cell from a patient, reprogram it into a stem cell and then turn these into specifically matched blood cells for transplant, preventing complications from mismatched donors.
“By joining forces with Retro Biosciences, we are now on our way to providing personalised, patient-specific blood stem cells to treat children and adults with blood diseases. A goal of the partnership is to progress this research into the first-in-human clinical trials within the next five years.”
Retro Biosciences’ mission is to add 10 years to the healthy human lifespan with programs that strive to replace malfunctioning cells through the use of stem cell technologies. Their licensing of MCRI’s breakthrough technology and investment in the organisation’s world-class stem cell research not only addresses urgent unmet needs in hematology but also represents a critical step toward enabling regenerative solutions that support a longer, healthier lifespan.
Retro Biosciences Co-founder and CEO Joe Betts-LaCroix said; “For decades, it’s been a dream of the stem cell field to convert pluripotent stem cells into blood stem cells that engraft permanently and produce all the needed blood lineages to maintain a person’s health.
“Last year, the principal investigators at MCRI finally cracked this code, and we immediately saw the potential for sustaining a healthy blood system into late life. Our team at Retro is incredibly excited to be the exclusive licensee for this new generation of autologous therapies.”
MCRI Professor Enzo Porrello, Director of Stem Cell Medicine, said the partnership demonstrated the value of early investment in transformative technologies and the importance of industry partnerships to drive innovative therapies towards clinical application.
Available for interview:
Associate Professor Elizabeth Ng, MCRI Group Leader, Blood Development
Professor Andrew Elefanty, MCRI Group Leader, Blood Development
Professor Ed Stanley, MCRI Deputy Stem Cell Medicine Theme Director and Group Leader, Immune Development
Professor Enzo Porrello, MCRI Theme Director, Stem Cell Medicine
Joe Betts-LaCroix, Retro Biosciences Co-founder and CEO
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-05-19
Propaganda is not simply a tool of manipulation, and in fact a professor of communication suggests it may even be a necessary skill for any citizen to address global challenges.
After carrying out extensive research examining the role of mass persuasion in an era of viral videos, social media campaigns, and global messaging, Professor Nathan Crick says propaganda has become an inescapable part of modern life.
In Propaganda: The Basics, Professor Crick suggests propaganda is not merely a tool of deception and instead should be understood as a fundamental aspect of mass communication in a technological society.
Redefining propaganda for the digital ...
2025-05-19
Press release
Under embargo until 05:01 BST/00:01 ET 19th May
Robots learning without us? New study cuts humans from early testing
Humans no longer have exclusive control over training social robots to interact effectively, thanks to a new study from the University of Surrey and the University of Hamburg.
The study, which will be presented at this year’s IEEE International Conference on Robotics and Automation (ICRA), introduces a new simulation ...
2025-05-19
A powerful new short film, from the FutureNeuro Research Ireland Centre and RCSI University of Medicine and Health Sciences sheds light on the urgent need to address the impact of climate change on brain health.
Produced in collaboration with the International League Against Epilepsy (ILAE) Climate Change Commission, the film calls for urgent action to address the risks posed by rising global temperatures to people living with neurological conditions such as epilepsy, multiple sclerosis and dementia.
The film features leading experts including Professor David ...
2025-05-18
From cut flowers to felled timber, and from caught fish to butchered meat, we value nature most when it’s dead. But if we can change economic systems and mindsets in support of nature, our planet may start to recover – this is the message from a global team of experts.
The authors warn that a lack of an economic and market value for the living natural world has given free rein for the exploitation and destruction of the environment, at a huge cost for animals, plants, Indigenous Peoples, and ultimately, all life on Earth.
A forthcoming book, ...
2025-05-18
About The Study: A new chronic obstructive pulmonary disease (COPD) diagnostic schema integrating respiratory symptoms, respiratory quality of life, spirometry, and structural lung abnormalities on computed tomographic imaging newly classified some individuals as having COPD. These individuals had an increased risk of all-cause and respiratory-related death, frequent exacerbations, and rapid lung function decline compared with individuals classified as not having COPD. Some individuals with airflow obstruction ...
2025-05-18
EMBARGOED UNTIL: 9:15 a.m., Sunday, May 18, 2025
Session: A20—Innovating Sleep Diagnostics: Emerging Approaches from Acoustics to Retinal Imaging
Sensor-Based Digital Health Technology Enables Digital Medicine for Sleep-Related Breathing Diseases
Date and Time: Sunday, May 18, 2025, 9:15 a.m.
Location: Room 303 (South Building, Level 3), Moscone Center
ATS 2025, San Francisco – A wearable pulse oximeter and connected software platform show promise for monitoring obstructive sleep apnea (OSA) and other sleep-related ...
2025-05-18
EMBARGOED UNTIL: 9:15 a.m. PT/12:15 p.m. ET, Sunday, May 18, 2025
WAITLIST DEATHS DROPPED UNDER NEW LUNG TRANSPLANT ALLOCATION SYSTEM
Session: A14—Advances in the Diagnosis and Management of ILD
Improvement in Wait List Mortality for the Most Critically Ill Since the Implementation of the CAS
Date and Time: Sunday, May 18, 2025, 9:15 a.m.
Location: Room 25, Hall E (North Building, Exhibition Level), Moscone Center
ATS 2025, San Francisco – Two years ago the United Network for Organ Sharing implemented new allocation guidelines for lung transplants that prioritize medical urgency. Now ...
2025-05-18
EMBARGOED UNTIL: 9:15 a.m. PT/12:15 p.m. ET, Sunday, May 18, 2025
Session: A14—Advances in the Diagnosis and Management of ILD
Methotrexate Versus Prednisone as First-line Treatment for Pulmonary Sarcoidosis: The Predmeth Trial
Date and Time: Sunday, May 18, 2025, 9:15 a.m.
Location: Room 25, Hall E (North Building, Exhibition Level), Moscone Center
ATS 2025, San Francisco – Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International Conference finds that methotrexate provides ...
2025-05-18
Belgrade, Serbia – 18 May 2025. Waist-to-height ratio predicts heart failure incidence, according to research presented today at Heart Failure 2025,1 a scientific congress of the European Society of Cardiology (ESC).
Obesity affects a substantial proportion of patients with heart failure (HF) and it has been reported that the risk of HF increases as body mass index (BMI) increases.2 Study presenter, Dr. Amra Jujic from Lund University, Malmö, Sweden, explained why the current analysis was carried out: “BMI is the most common measure ...
2025-05-18
Session: A109—Smoke, Snooze, and ICU Blues: The Influence of Environmental Exposures and Critical Care Conditions on Sleep
Rising Temperatures Are Associated with Increased Burden of Obstructive Sleep Apnea
Date and Time: Sunday, May 18, 2025, 2:15 p.m.
Location: Room 2022/2024 (West Building, Level 2), Moscone Center
ATS 2025, San Francisco – Rising temperatures increase the severity of obstructive sleep apnea (OSA), according to a large new study published at the ATS 2025 International Conference. The study also found that, under the most likely climate ...
LAST 30 PRESS RELEASES:
[Press-News.org] New US$35M partnership to advance blood disorder therapies
